Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-09-28

Clinical Trial Update: Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating riluzole for unresectable stage III/IV melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Riluzole (riluzole)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED | Results posted: 2022-09-28